摘要:
The invention describes the use of Tetrahydrobiopterin (BH4) or derivatives thereof for the treatment of COPD. In a preferred embodiment, BH4 or derivates thereof are combined with arginine or derivatives thereof.
摘要:
The invention relates to the use of certain PDE4 inhibitors alone or in combination with one or more differentiation inducing agents and/or an agent effective in raising intracellular concentrations of cAMP or a stable analogue of cAMP in the preparation of pharmaceutical compositions for the treatment of neoplasms of lymphoid cells.
摘要:
The invention describes the use of a PDE4 inhibitor in combination with BH4 or a BH4 derivative for the prevention and/or treatment of respiratory diseases.
摘要:
The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental.
摘要:
The invention relates to the combined administration of PDE inhibitors and &bgr;2 adrenoceptor agonists for the treatment of respiratory tract disorders.
摘要:
The invention relates to the combined administration of PDE inhibitors and β2 adrenoceptor agonists for the treatment of respiratory tract disorders.
摘要:
The invention relates to substituted diaminopyrimidine compounds, which are effective therapeutic compounds for treating diseases and disorders associated with those commonly treated by Protein Kinase C theta (PKCθ) inhibitors.
摘要:
A diseased state based on acute or chronic obstruction of vessels and/or bronchi, acute or chronic inflammation and/or edema formation is advantageously treated by the combined administration of a PDE inhibitor with either an adenylate cyclase agonist or a guanylate cyclase agonist to a subject in need of such therapy. Administration can be either concurrent or in either order.